Hematological Malignant Disease

Although we are only a few years into the 21st century, there has already been a great deal of progress in the treatment of hematological malignant diseases.

The discovery of new prognostic factors, especially in chronic lymphocytic leukemia, the advances in the new techniques to study minimal residual diseases routinely used as RTPCR(Reverse Transciptase Polymerase Chain Reaction) and fl ow cytometry in chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia and pediatric malignant diseases. Also, the discovery of new drugs such as monoclonal antibodies (anti CD20, anti CD33, anti CD52) as well as molecular target drugs as Imatinib have produced major improvements in the hematological and molecular remission and disease-free survival of diseases such as chronic lymphocytic leukemia, chronic myeloid leukemia, lymphomas and acute myeloid leukemia. All these advances will be exposed by world experts Doctors Kanti Rai, Alfred Reiter and Charles Schiffer during the conference. I hope that all the new information will stimulate a fruitful discussion between speakers and participants.

People with hematological malignancies need access to high quality cancer care, and ensuring that knowledge of care is updated is one of the highest priorities of the European School of Oncology and FUNDALEU.

VENUE
Alvear Palace Hotel
Avenida Alvear 1891
(1129) Buenos Aires
Argentina
Tel: +54 11 4808 2100
Fax: +54 11 4804 7777
www.alvearpalace.com

ORGANISING SECRETARIAT
Graciela Enrico
Secretary to Dr. Pavlovsky
FUNDALEU – “Angélica Ocampo